Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Olympus ( (JP:7733) ) has provided an announcement.
Olympus Corporation has announced a joint venture with Revival Healthcare Capital to develop endoluminal robotic surgery products through Swan EndoSurgical, Inc. This strategic investment aims to strengthen Olympus’s position in the MedTech industry by capitalizing on the growing market for minimally invasive surgical solutions, with potential investments reaching up to $458 million over six years. The venture underscores Olympus’s commitment to advancing medical technology and improving patient outcomes.
The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.
More about Olympus
Olympus Corporation is a global MedTech company focused on gastroenterology, urology, and respiratory medical products. The company aims to enhance its presence in long-term growth markets by investing in innovative technologies such as endoluminal robotics to improve minimally invasive endoscopic surgery.
Average Trading Volume: 4,524,056
Technical Sentiment Signal: Sell
Current Market Cap: Yen2045B
See more data about 7733 stock on TipRanks’ Stock Analysis page.